Journal
BRITISH JOURNAL OF CANCER
Volume 99, Issue 8, Pages 1330-1339Publisher
SPRINGERNATURE
DOI: 10.1038/sj.bjc.6604565
Keywords
neuroendocrine tumours; gene expression; microarray; neuroendocrine markers; cell lines
Categories
Funding
- Norwegian Foundation for Health and Rehabilitation
- The Norwegian Cancer Society
- The Norwegian Research Council
- Cancer Fund at the St Olavs Hospital HF, Trondheim
Ask authors/readers for more resources
Neuroendocrine tumours (NETs) comprise a heterogenous group of malignancies with an often unpredictable course, and with limited treatment options. Thus, new diagnostic, prognostic, and therapeutic markers are needed. To shed new lights into the biology of NETs, we have by cDNA transcript profiling, sought to identify genes that are either up- or downregulated in NE as compared with non-NE tumour cells. A panel of six NET and four non-NET cell lines were examined, and out of 12 743 genes examined, we studied in detail the 200 most significantly differentially expressed genes in the comparison. In addition to potential new diagnostic markers (NEFM, CLDN4,PEROX2), the results point to genes that may be involved in the tumorigenesis (BEX1, TMEPA1, FOSL1, RAB32), and in the processes of invasion, progression and metastasis (MME, STAT3, DCBLD2) of NETs. Verification by real time qRT-PCR showed a high degree of consistency to the microarray results. Furthermore, the protein expression of some of the genes were examined. The results of our study has opened a window to new areas of research, by uncovering new candidate genes and proteins to be further investigated in the search for new prognostic, predictive, and therapeutic markers in NETs.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available